Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study.

摘要: Background: The benefits of pimobendan in the treatment congestive heart failure (CHF) cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively. Hypothesis/objectives: To investigate effects HCM and recent CHF to identify possible endpoints for a pivotal study. We hypothesized that would be well-tolerated associated improved outcome. Animals: Eighty-three recently controlled CHF: 30 53 without left ventricular outflow tract obstruction. Methods: Prospective randomized placebo-controlled double-blind multicenter nonpivotal field Cats received either (0.30 mg/kg q12h, n = 43), placebo (n 39), or no medication 1) together furosemide (<10 mg/kg/d) clopidogrel. primary endpoint was successful outcome (ie, completing 180-day study period dose escalation furosemide). Results: proportion full analysis set population different between groups (P .75). For nonobstructive cats, success rate 32% pimobendan-treated versus 18.2% group (odds ratio [OR], 2.12; 95% confidence interval [CI], 0.54-8.34). obstructive 28.6% 60% groups, respectively (OR, 0.27; CI, 0.06-1.26). No difference found treatments secondary time death .89). Results were similar per-protocol sets. Adverse events both similar. Conclusions clinical importance: In this CHF, benefit on identified.